PEG-MGF

Other Research Peptides

aka Pegylated MGF · PEGylated Mechano-Growth Factor · Long-acting MGF derivative

Compare

Formula

—

MW (Da)

—

Half-life

~1–3 days (PEG-extended; varies with PEG size)

Saves

Overview

PEG-MGF is a pegylated MGF derivative intended to preserve or extend the activity window of native MGF-like signaling. The design rationale (PEGylation as a half-life-extension strategy) is scientifically reasonable, but that does not mean PEG-MGF itself has a validated human pharmacokinetic or therapeutic profile.

Mechanism

The claimed mechanism is essentially "MGF, but longer acting." Pegylation may reduce rapid clearance and proteolytic loss, extending tissue exposure relative to a very short-lived native-growth-factor signal. Publicly retrievable evidence is thin and mostly indirect. Anti-doping researchers have identified performance-enhancing MGF derivatives in the wild, and FDA states it has not identified human exposure data for compounded PEG-MGF drug products — sharply limiting confidence in both claimed benefits and risk estimates.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

PEGylation rationale is well-established in peptide pharmacology

PEGylation is a well-established half-life-extension strategy for peptides and proteins generally, so the conceptual rationale for PEG-MGF is plausible.

[pegmgf-pmc-pegrationale]

preclinical

Identified by anti-doping researchers as a performance-enhancing derivative

Anti-doping researchers have identified performance-enhancing MGF derivatives in the wild — establishing real-world use but not therapeutic legitimacy.

[pegmgf-pubmed-antidoping]

preclinical

Reported side effects

FDA: immunogenicity risk and absent human exposure data
clinical
FDA states compounded PEG-MGF may pose significant immunogenicity risk for some routes, raise peptide-impurity and API-characterization concerns, and notes absent human exposure data — so there is no evidence-based standard human dose.
No regulator-vetted "protocol"
anecdotal
Any source presenting a routine "protocol" for PEG-MGF is not anchored in an approved label or an established clinical evidence base.

Dosing notes

No evidence-based standard human dose exists. FDA states it has not identified human exposure data for compounded PEG-MGF drug products. Any published "protocol" lacks regulator support or established clinical evidence.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

No validated product-specific storage instructions located. Defensible default: cold, dry, light-protected raw material, usually -20°C or below; aliquot and avoid repeated freeze-thaw after reconstitution.

Vendors carrying PEG-MGF

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about PEG-MGF.

No questions yet. Be the first to ask.

References

[pegmgf-pmc-pegrationale]
PEGylation as a peptide half-life extension strategy
Review authors per PMC entry · PubMed Central
Source
[pegmgf-pubmed-antidoping]
Anti-doping detection of performance-enhancing MGF derivatives
Authors per PubMed entry · PubMed
Source
[pegmgf-fda-bulk]
FDA: certain bulk drug substances for use in compounding may present significant safety risks
U.S. FDA · FDA
Source